The prognostic system for CMML generally included clinical features and lab findings, such as blood/bone marrow biopsies, as well as mutations in ASXL1, NRAS, RUNX1, and SETBP1 et al. [15–20]. This evidence concerns the gene ASXL1 and chronic myelomonocytic leukemia.